{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:12:22Z","timestamp":1778587942831,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of North Carolina at Chapel Hill Department of Medicine Physician Science Training Program","award":["University of North Carolina at Chapel Hill Department of Medicine Physician Science Training Program"],"award-info":[{"award-number":["University of North Carolina at Chapel Hill Department of Medicine Physician Science Training Program"]}]},{"DOI":"10.13039\/100011072","name":"Center for AIDS Research, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["P30-AI050410"],"award-info":[{"award-number":["P30-AI050410"]}],"id":[{"id":"10.13039\/100011072","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Differentiated Service Delivery (DSD) Programme of IAS \u2013 the International AIDS Society","award":["Differentiated Service Delivery (DSD) Programme of IAS \u2013 the International AIDS Society"],"award-info":[{"award-number":["Differentiated Service Delivery (DSD) Programme of IAS \u2013 the International AIDS Society"]}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2020143"],"award-info":[{"award-number":["2020143"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32-AI007001"],"award-info":[{"award-number":["T32-AI007001"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The integration of HIV pre-exposure prophylaxis (PrEP) into STI services can improve PrEP uptake among a population at elevated risk of acquiring HIV. The effectiveness of PrEP relies on ongoing coverage during periods of HIV risk, however, and little is known about longitudinal PrEP use among people accessing PrEP through STI clinics in sub-Saharan Africa. In this study, we analyzed routine records data from people who newly initiated PrEP at an STI clinic in Lilongwe, Malawi in March-December 2022. We assessed PrEP persistence among clients who received Malawi\u2019s standard-of-care PrEP services (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009662) and reweighted the data to reflect the baseline distribution of age, sex, and PrEP indication among the full study population (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009835). We used weighted generalized estimating equations to estimate the proportion of clients expected to persist on PrEP if all clients had received Malawi\u2019s standard-of-care services. We also assessed predictors of persistence and described re-engagement in PrEP among clients who did not persist. We estimated that, had all clients received standard-of-care services, 17% (95% CI: 14%, 20%), 7% (95% CI: 6%, 10%), and 4% (95% CI: 3%, 5%) would have persisted on PrEP at 1, 3, and 6 months, respectively, and that 8% (95% CI: 5%, 11%) of those who did not persist on PrEP at 1 month would have re-engaged in PrEP services by 12 months. Persistence varied by age and PrEP indication. Our findings indicate very low PrEP persistence in this population and suggest opportunities to support ongoing PrEP use in settings with integrated PrEP\/STI services.\n                  <\/jats:p>","DOI":"10.1007\/s10461-025-04937-y","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T03:19:25Z","timestamp":1764386365000},"page":"1327-1337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poor Oral HIV Pre-Exposure Prophylaxis (PrEP) Persistence in an Integrated PrEP\/STI Program in Malawi"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0046-2144","authenticated-orcid":false,"given":"Grace E.","family":"Mulholland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Matoga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Mathiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Griffin J.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Ndalama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapiwa","family":"Munthali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Nyirenda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Bonongwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Jere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakaliah","family":"Mphande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irving F.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Rutstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"4937_CR1","unstructured":"Fact Sheet 2025: Global HIV Statistics [Internet]. UNAIDS; 2025. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/2025-07\/2025_Global_HIV_Factsheet_en.pdf"},{"key":"4937_CR2","doi-asserted-by":"publisher","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"E O Murchu","year":"2022","unstructured":"O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12:e048478.","journal-title":"BMJ Open"},{"key":"4937_CR3","doi-asserted-by":"crossref","unstructured":"Montgomery MC, Oldenburg CE, Nunn AS, Mena L, Anderson P, Liegler T et al. Adherence to pre-Exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11.","DOI":"10.1371\/journal.pone.0157742"},{"key":"4937_CR4","unstructured":"Centers for Disease Control and Prevention. PrEP Effectiveness [Internet]. CDC HIV Basics. 2022. Available from: https:\/\/www.cdc.gov\/hiv\/basics\/prep\/prep-effectiveness.html"},{"key":"4937_CR5","doi-asserted-by":"crossref","unstructured":"Lazarus E, Otwombe K, Dietrich J, Andrasik MP, Morgan CA, Kublin JG et al. Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa. South Afr J HIV Med [Internet]. 2019 [cited 2024 May 23];20. Available from: https:\/\/sajhivmed.org.za\/index.php\/hivmed\/article\/view\/866","DOI":"10.4102\/sajhivmed.v20i1.866"},{"key":"4937_CR6","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/ije\/dyq057","volume":"39","author":"RF Baggaley","year":"2010","unstructured":"Baggaley RF, White RG, Boily M-C. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39:1048\u201363.","journal-title":"Int J Epidemiol"},{"key":"4937_CR7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1111\/tbed.13621","volume":"67","author":"AF Kabapy","year":"2020","unstructured":"Kabapy AF, Shatat HZ, Abd El-Wahab EW. Attributes of HIV infection over decades (1982\u20132018): a systematic review and meta\u2010analysis. Transbound Emerg Dis. 2020;67:2372\u201388.","journal-title":"Transbound Emerg Dis"},{"key":"4937_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","volume":"20","author":"KJ Looker","year":"2020","unstructured":"Looker KJ, Welton NJ, Sabin KM, Dalal S, Vickerman P, Turner KME, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020;20:240\u20139.","journal-title":"Lancet Infect Dis"},{"key":"4937_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/sextrans-2018-053713","volume":"95","author":"SC Masha","year":"2019","unstructured":"Masha SC, Cools P, Sanders EJ, Vaneechoutte M, Crucitti T. Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2019;95:36\u201342.","journal-title":"Sex Transm Infect"},{"key":"4937_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/sextrans-2020-054706","volume":"97","author":"MY Wu","year":"2021","unstructured":"Wu MY, Gong HZ, Hu KR, Zheng H-Y, Wan X, Li J. Effect of syphilis infection on HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2021;97:525\u201333.","journal-title":"Sex Transm Infect"},{"key":"4937_CR11","unstructured":"WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection. Module 13. Integrating STI services [Internet]. Geneva: World Health Organization. 2022 Sep. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240057425"},{"key":"4937_CR12","doi-asserted-by":"crossref","unstructured":"Anand P, Wu L, Mugwanya K. Integration of sexually transmitted infection and HIV pre-exposure prophylaxis services in sub-Saharan Africa: a scoping review. Front Reprod Health [Internet]. 2023;5. Available from: https:\/\/www.scopus.com\/pages\/publications\/85164916109?inward","DOI":"10.3389\/frph.2023.944372"},{"key":"4937_CR13","doi-asserted-by":"crossref","unstructured":"Rutstein SE, Matoga M, Chen JS, Mathiya E, Ndalema B, Nyirenda N et al. Integrating enhanced HIV pre-exposure prophylaxis into a sexually transmitted infection clinic in Lilongwe (ePrEP STI): a prospective cohort study (Preprint). JMIR Res Protoc. 2022.","DOI":"10.2196\/preprints.37395"},{"key":"4937_CR14","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9:e254\u201368.","journal-title":"Lancet HIV"},{"key":"4937_CR15","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1007\/s10461-022-03966-1","volume":"27","author":"E Heilmann","year":"2023","unstructured":"Heilmann E, Okuku J, Itoh M, Hines JZ, Prieto JT, Phiri M, et al. Measuring oral pre-exposure prophylaxis (PrEP) continuation through electronic health records during program Scale-Up among the general population in Zambia. AIDS Behav. 2023;27:2390\u20136.","journal-title":"AIDS Behav"},{"key":"4937_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1186\/s12879-022-07658-y","volume":"22","author":"BG Rogers","year":"2022","unstructured":"Rogers BG, Sosnowy C, Zanowick-Marr A, Chan PA, Mena LA, Patel RR, et al. Facilitators for retaining men who have sex with men in pre-exposure prophylaxis care in real world clinic settings within the united States. BMC Infect Dis. 2022;22:673.","journal-title":"BMC Infect Dis"},{"key":"4937_CR17","doi-asserted-by":"crossref","unstructured":"Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. Garcia-Lerma JG, editor. PLOS ONE. 2015;10:e0125458.","DOI":"10.1371\/journal.pone.0125458"},{"key":"4937_CR18","doi-asserted-by":"publisher","first-page":"e25252","DOI":"10.1002\/jia2.25252","volume":"22","author":"KC Coy","year":"2019","unstructured":"Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a National sample of 7148 PrEP users, united States, 2015 to 2017. J Int AIDS Soc. 2019;22:e25252.","journal-title":"J Int AIDS Soc"},{"key":"4937_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1071\/SH21207","volume":"19","author":"K Chidwick","year":"2022","unstructured":"Chidwick K, Pollack A, Busingye D, Norman S, Grulich A, Bavinton B, et al. Utilisation of pre-exposure prophylaxis (PrEP) for HIV prevention in the Australian general practice setting: a longitudinal observational study. Sex Health. 2022;19:101\u201311.","journal-title":"Sex Health"},{"key":"4937_CR20","doi-asserted-by":"crossref","unstructured":"Hendrickson C, Hirasen K, Mongwenyana C, Benade M, Bothma R, Smith C et al. Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa. MedRxiv Prepr. Serv. Health Sci. United States; 2023. p. 2023.08.14.23294055.","DOI":"10.1101\/2023.08.14.23294055"},{"key":"4937_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","volume":"82","author":"PR Rosenbaum","year":"1987","unstructured":"Rosenbaum PR. Model-Based direct adjustment. J Am Stat Assoc. 1987;82:387\u201394.","journal-title":"J Am Stat Assoc"},{"key":"4937_CR22","unstructured":"AIDSinfo: Global data on HIV epidemiology and response [Internet]. 2024. Available from: https:\/\/aidsinfo.unaids.org\/"},{"key":"4937_CR23","unstructured":"Malawi National Strategic Plan for HIV and AIDS: Revised and Extended Strategy for 2023\u20132027 [Internet]. Malawi Ministry of Health, Malawi National AIDS Commission. 2023. Available from: https:\/\/www.prepwatch.org\/resources\/malawi-hiv-aids-national-strategic-plan-2023-27\/"},{"key":"4937_CR24","unstructured":"Malawi Ministry of Health and Population. National guidelines for the provision of oral pre-exposure prophylaxis for individuals at substantial risk of HIV in Malawi. 2020."},{"key":"4937_CR25","unstructured":"Malawi service delivery guidelines and standard operating procedures for the provision of HIV pre-exposure prophylaxis using oral or long-acting injectable options. Malawi Ministry of Health; 2024."},{"key":"4937_CR26","doi-asserted-by":"crossref","unstructured":"Krakower D, Maloney KM, Powell VE, Levine K, Grasso C, Melbourne K et al. Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care. J Int AIDS Soc. 2019;22.","DOI":"10.1002\/jia2.25250"},{"key":"4937_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2352-4642(20)30248-0","volume":"4","author":"K Gill","year":"2020","unstructured":"Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, et al. Acceptability, safety, and patterns of use of oral Tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Health. 2020;4:875\u201383.","journal-title":"Lancet Child Adolesc Health"},{"key":"4937_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411\u201322.","journal-title":"N Engl J Med"},{"key":"4937_CR29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.ogx.0000466878.37011.6f","volume":"70","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. Obstet Gynecol Surv. 2015;70:444\u20136.","journal-title":"Obstet Gynecol Surv"},{"key":"4937_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423\u201334.","journal-title":"N Engl J Med"},{"key":"4937_CR31","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/cid\/ciu916","volume":"60","author":"SM Seifert","year":"2015","unstructured":"Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis. 2015;60:804\u201310.","journal-title":"Clin Infect Dis"},{"key":"4937_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1089\/aid.2016.0008","volume":"32","author":"SM Seifert","year":"2016","unstructured":"Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32:981\u201391.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4937_CR33","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jech.2004.029496","volume":"60","author":"MA Hernan","year":"2006","unstructured":"Hernan MA. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60:578\u201386.","journal-title":"J Epidemiol Community Health"},{"key":"4937_CR34","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC T","year":"2012","unstructured":"T MC, K PM, P LA, S DK, R CE. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423\u201334.","journal-title":"N Engl J Med"},{"key":"4937_CR35","doi-asserted-by":"crossref","unstructured":"Cabral A, Baeten M, Ngure J, Velloza K, Odoyo J, Haberer JE et al. J, Intimate partner violence and self-reported pre-exposure prophylaxis interruptions among HIV-negative partners in HIV serodiscordant couples in Kenya and Uganda. J Acquir Immune Defic Syndr. 1999. 2018;77:154\u20139.","DOI":"10.1097\/QAI.0000000000001574"},{"key":"4937_CR36","doi-asserted-by":"publisher","first-page":"e1002444","DOI":"10.1371\/journal.pmed.1002444","volume":"14","author":"R Eakle","year":"2017","unstructured":"Eakle R, Gomez GB, Naicker N, Bothma R, Mbogua J, Cabrera Escobar MA, et al. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South africa: results from a prospective observational demonstration project. PLoS Med. 2017;14:e1002444.","journal-title":"PLoS Med"},{"key":"4937_CR37","doi-asserted-by":"publisher","first-page":"e25261","DOI":"10.1002\/jia2.25261","volume":"22","author":"R Heffron","year":"2019","unstructured":"Heffron R, Ngure K, Velloza J, Kiptinness C, Quame-Amalgo J, Oluch L, et al. Implementation of a comprehensive safer conception intervention for HIV\u2010serodiscordant couples in kenya: uptake, use and effectiveness. J Int AIDS Soc. 2019;22:e25261.","journal-title":"J Int AIDS Soc"},{"key":"4937_CR38","doi-asserted-by":"publisher","first-page":"e25588","DOI":"10.1002\/jia2.25588","volume":"23","author":"J Kagaayi","year":"2020","unstructured":"Kagaayi J, Batte J, Nakawooya H, Kigozi B, Nakigozi G, Str\u00f6mdahl S, et al. Uptake and retention on HIV pre-exposure prophylaxis among key and priority populations in South-Central Uganda. J Int AIDS Soc. 2020;23:e25588.","journal-title":"J Int AIDS Soc"},{"key":"4937_CR39","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/S2352-3018(19)30433-3","volume":"7","author":"CA Koss","year":"2020","unstructured":"Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, et al. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV. 2020;7:e249\u201361.","journal-title":"Lancet HIV"},{"key":"4937_CR40","doi-asserted-by":"crossref","unstructured":"Lahuerta M, Zerbe A, Baggaley R, Falcao J, Ahoua L, DiMattei P et al. Feasibility, acceptability, and adherence with short-term HIV preexposure prophylaxis in female sexual partners of migrant miners in mozambique. J Acquir Immune Defic Syndr. 1999. 2017;76:343\u20137.","DOI":"10.1097\/QAI.0000000000001518"},{"key":"4937_CR41","doi-asserted-by":"publisher","first-page":"e25208","DOI":"10.1002\/jia2.25208","volume":"21","author":"A Mboup","year":"2018","unstructured":"Mboup A, B\u00e9hanzin L, Gu\u00e9dou FA, Geraldo N, Goma-Mats\u00e9ts\u00e9 E, Gigu\u00e8re K, et al. Early antiretroviral therapy and daily pre-exposure prophylaxis for HIV prevention among female sex workers in Cotonou, benin: a prospective observational demonstration study. J Int AIDS Soc. 2018;21:e25208.","journal-title":"J Int AIDS Soc"},{"key":"4937_CR42","doi-asserted-by":"publisher","first-page":"e1002885","DOI":"10.1371\/journal.pmed.1002885","volume":"16","author":"KK Mugwanya","year":"2019","unstructured":"Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya. PLoS Med. 2019;16:e1002885.","journal-title":"PLoS Med"},{"key":"4937_CR43","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/0956462420943704","volume":"31","author":"M Sarr","year":"2020","unstructured":"Sarr M, Gueye D, Mboup A, Diouf O, Bao MDB, Ndiaye AJ, et al. Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal. Int J STD AIDS. 2020;31:1063\u201372.","journal-title":"Int J STD AIDS"},{"key":"4937_CR44","first-page":"712","volume":"33","author":"J de Dieu Tapsoba","year":"2021","unstructured":"de Dieu Tapsoba J, Zangeneh SZ, Appelmans E, Pasalar S, Mori K, Peng L, et al. Persistence of oral pre-exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care - Psychol Socio-Med Asp AIDSHIV. 2021;33:712\u201320.","journal-title":"AIDS Care - Psychol Socio-Med Asp AIDSHIV"},{"key":"4937_CR45","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/QAD.0000000000003500","volume":"37","author":"A Rao","year":"2023","unstructured":"Rao A, Lesko C, Mhlophe H, Rucinski K, Mcingana M, Pretorius A, et al. Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa. AIDS Lond Engl. 2023;37:977\u201386.","journal-title":"AIDS Lond Engl"},{"key":"4937_CR46","doi-asserted-by":"publisher","first-page":"e25827","DOI":"10.1002\/jia2.25827","volume":"24","author":"JB Reed","year":"2021","unstructured":"Reed JB, Shrestha P, Were D, Chakare T, Mutegi J, Wakhutu B, et al. HIV PrEP is more than ART-lite: longitudinal study of real\u2010world PrEP services data identifies missing measures meaningful to HIV prevention programming. J Int AIDS Soc. 2021;24:e25827.","journal-title":"J Int AIDS Soc"},{"key":"4937_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/QAI.0000000000000362","volume":"67","author":"A Corneli","year":"2014","unstructured":"Corneli A, Wang M, Agot K, Ahmed K, Lombaard J, Van Damme L. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. JAIDS J Acquir Immune Defic Syndr. 2014;67:555\u201363.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"4937_CR48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","volume":"29","author":"JE Haberer","year":"2015","unstructured":"Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS Lond Engl. 2015;29:1277\u201385.","journal-title":"AIDS Lond Engl"},{"key":"4937_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jiw077","volume":"214","author":"ML Cottrell","year":"2016","unstructured":"Cottrell ML, Yang KH, Prince HMA, Sykes C, White N, Malone S, et al. A translational Pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using Tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55\u201364.","journal-title":"J Infect Dis"},{"key":"4937_CR50","unstructured":"Impact of PEPFAR Stop Work Orders on PrEP [Internet]. PrEPWatch. 2025 [cited 2025 Jul 16]. Available from: https:\/\/www.prepwatch.org\/pepfar-stop-work\/"},{"key":"4937_CR51","unstructured":"2025 Global AIDS, Update. AIDS, Crisis and the power to transform [Internet]. UNAIDS; 2025 Jul. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2025\/2025-global-aids-update"},{"key":"4937_CR52","doi-asserted-by":"crossref","unstructured":"Rutstein SE, Pettifor AE, Phiri S, Kamanga G, Hoffman IF, Hosseinipour MC et al. Incorporating acute HIV screening into routine HIV testing at sexually transmitted infection clinics, and HIV testing and counseling centers in Lilongwe, Malawi. J Acquir Immune Defic Syndr. 1999. 2016;71:272\u201380.","DOI":"10.1097\/QAI.0000000000000853"},{"key":"4937_CR53","doi-asserted-by":"crossref","unstructured":"Mbilizi Chimwaza YR, Dadabhai SS, Nyondo Mipando AL, Mbeda C, Panchia R, Lucas JP et al. HIV risk perception and sexual behavior among HIV-uninfected men and transgender women who have sex with men in sub-Saharan Africa: findings from the HPTN 075 qualitative sub-study. Newman PA, editor. PLOS Glob Public Health. 2022;2:e0001408.","DOI":"10.1371\/journal.pgph.0001408"},{"key":"4937_CR54","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1521\/aeap.2024.36.1.33","volume":"36","author":"P D\u2019Avanzo","year":"2024","unstructured":"D\u2019Avanzo P, Shourya S, Brin M, Kaw S, Kay E, Batey DS, et al. Identifying key factors to PrEP initiation and persistence among YMSM through focus groups and surveys in two high-priority settings. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 2024;36:33\u201347.","journal-title":"AIDS Educ Prev Off Publ Int Soc AIDS Educ"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04937-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04937-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04937-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:33:17Z","timestamp":1778585597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04937-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4937"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04937-y","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted using data obtained for clinical purposes, abstracted with a waiver of informed consent. The study was approved by the University of North Carolina at Chapel Hill Biomedical Institutional Review Board (21-2457) and Malawi National Health Services Research Committee (21\/09\/2777).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}